Сhronic pancreatitis Lykhatska G.V.. Pancreatic structure and function.
Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled
description
Transcript of Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled
![Page 1: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/1.jpg)
Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled
Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
Featured Article:
Itamar Raz, Deepak L. Bhatt, Boaz Hirshberg, Ofri Mosenzon, Benjamin M. Scirica, Amarachi Umez-Eronini, KyungAh Im, Christina Stahre, Alona
Buskila, Nayyar Iqbal, Norton Greenberger, and Markus M. Lerch
Diabetes Care Volume 37: 2435-2441
September, 2014
![Page 2: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/2.jpg)
STUDY OBJECTIVE
• To determine the incidence of pancreatitis and pancreatic cancer in the SAVORTIMI 53 trial
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 3: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/3.jpg)
STUDY DESIGN AND METHODS
• 16,492 type 2 diabetic patients ≥40 years old with cardiovascular (CV) disease or CV risk factors were randomized to saxagliptin or placebo
• Patients were followed for 2.1 years
• Outcome measures were investigator-reported with blinded expert adjudication of total pancreatitis (acute and chronic) and reported cases of pancreatic cancer
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 4: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/4.jpg)
RESULTS
• Trial investigators reported 35 events of pancreatitis in each treatment arm in 63 patients
• Adjudication confirmed pancreatitis in 24 patients (26 events) in the saxagliptin arm and 21 patients (25 events) in the placebo arm
• Cases of definite acute pancreatitis were confirmed in 17 vs. 9, definite plus possible pancreatitis in 22 vs. 16, and chronic pancreatitis in 2 vs. 6 in the saxagliptin and placebo arms, respectively
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 5: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/5.jpg)
RESULTS
• No differences were found between treatment arms in the following:
• Time to event onset• Concomitant risk factors for pancreatitis• Investigator-reported causality from study medication or
disease severity• Outcome
• The investigators reported 5 and 12 cases of pancreatic cancer in the saxagliptin and placebo arms, respectively
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 6: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/6.jpg)
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 7: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/7.jpg)
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 8: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/8.jpg)
Raz I. et al. Diabetes Care 2014;37:2435-2441
![Page 9: Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled](https://reader036.fdocuments.us/reader036/viewer/2022082417/56813c5f550346895da5e48b/html5/thumbnails/9.jpg)
CONCLUSIONS
• Risk for pancreatitis in type 2 diabetic patients treated with saxagliptin was low and apparently similar to placebo
• There was no sign of increased risk for pancreatic cancer
• Further studies are needed to completely resolve the pancreatic safety issues with incretin-based therapy
Raz I. et al. Diabetes Care 2014;37:2435-2441